Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phibro Animal Health (PAHC) Finished Goods (2016 - 2026)

Phibro Animal Health has reported Finished Goods over the past 13 years, most recently at $309.7 million for Q4 2025.

  • For Q4 2025, Finished Goods rose 21.43% year-over-year to $309.7 million; the TTM value through Dec 2025 reached $309.7 million, up 21.43%, while the annual FY2025 figure was $253.8 million, 49.69% up from the prior year.
  • Finished Goods for Q4 2025 was $309.7 million at Phibro Animal Health, up from $279.6 million in the prior quarter.
  • Over five years, Finished Goods peaked at $309.7 million in Q4 2025 and troughed at $133.2 million in Q1 2021.
  • A 5-year average of $190.6 million and a median of $170.8 million in 2023 define the central range for Finished Goods.
  • Biggest five-year swings in Finished Goods: fell 3.0% in 2024 and later soared 63.76% in 2025.
  • Year by year, Finished Goods stood at $147.6 million in 2021, then grew by 16.81% to $172.4 million in 2022, then increased by 7.05% to $184.6 million in 2023, then skyrocketed by 38.16% to $255.0 million in 2024, then rose by 21.43% to $309.7 million in 2025.
  • Business Quant data shows Finished Goods for PAHC at $309.7 million in Q4 2025, $279.6 million in Q3 2025, and $253.8 million in Q2 2025.